Dick Cheney called hunting accident 'one of the worst' days of his life Sam Bankman-Fried, serving 25-year sentence, faces a ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis ...

Trybello has enhanced its Bello Hair Helper Spray, which now features a strengthened botanical blend designed to deliver visibly thicker, ...

Bittam offers up to 200x leverage with a zero-slippage index trading system , ensuring every order executes precisely at your ...

Ukrainian President Volodymyr Zelensky has confirmed the first combat use of Ukraine’s homegrown “Flamingo” and “Ruta” missiles, marking a major step in Kyiv’s bid for self-reliant defense amid ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

(RTTNews) - Johnson & Johnson (JNJ) released new 52-week Phase 3 results from the ICONIC-TOTAL study evaluating icotrokinra, a first-in-class oral peptide that selectively blocks the IL-23 receptor in ...

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as ...

Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) are set to seek a label expansion for their JAK inhibitor baricitinib, marketed ...

Rigetti is a quantum computing company that generates limited revenue but has a lot of long-term potential. Meanwhile, its losses are substantial, and the business may remain in the red for the ...

New results from Eli Lilly (LLY) and Incyte (INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients with severe alopecia areata achieve successful hair regrowth on ...

New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia ...